PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
29-Mar-2022 Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver Sanofi
29-Mar-2022 European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B CSL Behring
29-Mar-2022 Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency Sanofi
29-Mar-2022 Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020 Novo Holdings
29-Mar-2022 Oxurion to Participate in Needham Virtual Healthcare Conference Oxurion
29-Mar-2022 European marketing authorization application for MOB-015 submitted Moberg Pharma
29-Mar-2022 Publication of definitive end result for Vifor Pharma tender offer Vifor Pharma
29-Mar-2022 New Long-Term Complete Skin Clearance Data for BIMZELX®▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting Syneos Health
29-Mar-2022 Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies Almirall
29-Mar-2022 Oxurion Publishes 2021 Annual Report Oxurion
29-Mar-2022 Medios AG: Record year 2021 and positive outlook for 2022 Medios AG
29-Mar-2022 SYNLAB AG: SYNLAB partners with OncoDNA to provide comprehensive biomarker testing for cancer therapy selection in Germany SYNLAB AG
29-Mar-2022 Dermapharm Holding SE: Continuous growth of Group revenues and adjusted Group EBITDA in 2022 Dermapharm Holding SE
28-Mar-2022 Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence HAEMATO AG
28-Mar-2022 Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU Relief Therapeutics Holding SA
28-Mar-2022 Max Müller to be new CEO of TeleClinic, taking over from founder and former CEO Katharina Jünger Zur Rose Group AG
25-Mar-2022 ICR welcomes FDA approval of ‘search and destroy’ treatment The Institute of Cancer Research
25-Mar-2022 Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody Tiziana Life Sciences Ltd
25-Mar-2022 XFret Wins the 2021 Sustainability Award – Startup/Small Business Category TIACA
25-Mar-2022 TIACA Announces the Take-Off of the BlueSky Program TIACA